# Nautilus Biotechnology, Inc. (NAUT)

> Source: Nexqual · https://nexqual.com/NAUT · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Nautilus Biotechnology, Inc. (NAUT), nexqual.com/NAUT" · informational, not investment advice.

**Price:** USD 2.16 (+0.00% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.16 · day 1.88–2.2 · 52w 0.84–4.31 · market cap $275M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 3.83 (range 3.5–4).
- Total return with dividends: 1Y +101.9% vs S&P 500 +18.1%; 5Y -62.2% vs S&P 500 +85.1%.
- Next earnings: 2026-10-27, EPS estimate USD -0.14, revenue estimate $206K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 3.83 (low 3.5, high 4).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Roth Capital | Initiated | Buy | $3.5 |
| 2026-09-09 | Leerink Partners | Initiated | Outperform | $4 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +101.9% | -62.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +102.4% | -17.6% |
| Volatility (annualized) | 117.0% | 78.4% |
| Max drawdown | -78.4% (Mar 2026→Aug 2026) | -89.1% (Dec 2021→Sep 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/NAUT · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt